Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352155 | 0.95 | LMNA (0.58) | LMNACSNK1DALDH1A1KDM4EMEN1 | |
| SCHEMBL21723872 | 0.84 | LMNA (0.45) | LMNACSNK1DKDM4ETP53TSHR | |
| SCHEMBL22897231 | 0.84 | LMNA (0.45) | LMNACSNK1DTP53TSHRELANE | |
| SCHEMBL21724351 | 0.83 | LMNA (0.43) | LMNACSNK1DKDM4EHSD17B10TP53 | |
| SCHEMBL175330 | 0.83 | ALDH1A1 (0.46) | CSNK1DALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30871860 | 0.82 | LMNA (0.44) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18412911 | 0.81 | CRHR1 (0.35) | LMNA | |
| SCHEMBL31714691 | 0.81 | LMNA (0.44) | LMNAKDM4ETP53 | |
| SCHEMBL24612004 | 0.80 | NOTUM (0.42) | — | |
| SCHEMBL31714887 | 0.80 | TEAD2 (0.43) | CSNK1DALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885CSNK1D 1090/4885ALDH1A1 621/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | LMNA 2715/4885CSNK1D 3890/4885ALDH1A1 3562/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885CSNK1D 1090/4885ALDH1A1 621/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | LMNA 3393/4885CSNK1D 1978/4885ALDH1A1 3515/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885CSNK1D 1090/4885ALDH1A1 621/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | LMNA 2715/4885CSNK1D 3890/4885ALDH1A1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.